Outcomes 2019 - Baylor Scott & White Heart and Vascular Hospital BSWHHVH_646_2019 Outcomes JOOMAG MOD | Page 57

• Transcatheter aortic valve replacement (TAVR) • Transcatheter mitral valve repair (TMVR), especially for high surgical risk patients with severe mitral regurgitation • Minimally invasive aortic, mitral, pulmonic and tricuspid valve repair and replacement using sternal sparing, port-access approaches • Transcatheter valve-in-valve implantation for failed bioprosthetic valves in the aortic and mitral valves The Valve Disorders Center is supported by a team of coordinators and data analysts who continually review and report outcomes. Valve Disorders Center medical staff members (FY19): Farhan Ali, MD, MA, MPH, FACC, FSCAI, RPVI William Anderson, MD Sukesh Burjonroppa, MD, FACC, FSCAI Gonzalo V. Gonzalez-Stawinski, MD Vijay Kalaria, MD, FACC, FSCAI Abdul Keylani, MD Reza Khalafi, MD, FACS, FCCP Amir Malik MD, FACC, FSCAI Peggy McAtee, RN, ANP-BC Arun Padala, MD, FACC Jeffrey Wu, MD For fiscal year 2020, the team will include Anita Krueger, MD, and Daniel Martinez, MD. For the 24/7 referral line and patient support, call 817.825.1374. Email all questions to [email protected]. >130 (October 2017 – June 30, 2019) Median length of stay (FY19) : 1 day Post-minimally invasive valve replacement patients discharged home with no additional care required (FY19) : >80% Mitral valve program – total patients screened and assessed (FY19) : >160 The Valve Disorders Center at Baylor Scott & White Heart and Vascular Hospital – Fort Worth is a part of the comprehensive Structural Heart Disease Program. With referrals coming from all over Tarrant county and the western region of Texas, the Valve Disorders Center is comprised of a multidisciplinary team of clinicians, including cardiologists, interventional cardiologists, cardiothoracic surgeons, imaging specialists and cardiac care nurses. The multidisciplinary team meets to review each potential patient’s case and determine the most appropriate approach to valve repair or replacement. Therapies available include: Total number of implants: Total transcatheter mitral valve repair MitraClip ® **: 38 **MitraClip ® is the only minimally invasive mitral regurgitation treatment option approved by the Food and Drug Administration and commercially available. Valve Disorders Center 57